Third Harmonic Bio

United States
Primghar, Iowa, United States, 02139

Company profile

Third Harmonic Bio company profile

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2019-01-01, Year

Headquarters

Postal code
02139
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
2
Total equity funding
$155M
Last funding
Series B / $105M / 2022-01-16
Last equity funding
Series B / $105M
Investors
10
Lead investors
4
Articles
65
Exited on
2022-09-15

Founders and investors

Lead investors

Atlas VentureBiotechnology Value FundGeneral AtlanticOrbiMed

Investors

Commodore CapitalGeneral AtlanticOrbiMedRA Capital ManagementRTW Investments